The effect of @entity3303 sprayed on the major duodenal papilla on the frequency of post-ERCP XXXX .

@entity1 @entity1690 @entity788 @entity656 @entity3303 @entity8586
BACKGROUND: @entity656 remains a serious cause of ERCP-related morbidity. Topical application of @entity3303 reportedly blunts @entity8586 release from intestinal mucosa and reduces @entity1690 . A randomized trial was conducted to evaluate the effect of @entity3303 sprayed on the major duodenal papilla on the frequency of post-ERCP @entity788 . Secondary outcomes evaluated were ease of cannulation and severity of post-ERCP @entity788 . METHODS: @entity1 undergoing ERCP were randomized in blocks of 6 to have 10 mL of either 1% @entity3303 or normal saline solution sprayed on the major papilla before cannulation. @entity1 were observed for the development of post-ERCP @entity788 . @entity1 history- and procedure-related variables were recorded. RESULTS: A total of 326 @entity1 were enrolled, of whom 32 were excluded after randomization but before analysis. Of @entity1 analyzed, 145 were randomized to treatment with @entity3303 and 149 to placebo. No @entity1 was lost to follow-up. There was no significant difference noted in @entity1 history- or procedure-related variables. Seven @entity1 in the @entity3303 group and 5 in the placebo group developed post-ERCP @entity788 (p=0.73). Ease of cannulation did not differ between the two groups. CONCLUSIONS: @entity3303 sprayed on the major papilla does not decrease the frequency of post-ERCP @entity788 .
